RankAlpha logo
Back to Rankings

KURA

Kura OncologyB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The constructive case is that Kura now has both early commercial proof points for KOMZIFTI and fresh combination-data support for using ziftomenib more broadly across AML, while the balance sheet looks strong enough to carry the story toward larger registrational milestones. [#SEC-8K-2026-05-12] [#PR-EARNINGS-2026-06-11]
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -0.1.
What can break
Balance-sheet comfort partly depends on anticipated collaboration payments as well as trial timing, so runway is strong but not entirely frictionless.
Momentum
83
Value
41
Sentiment
52
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $11.00 · Bull $18.00 · Bear $6.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-18 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $31.17
Why
Momentum83 · Δ7d -0.1
Value41 · Δ7d -0.1
Sentiment52 · Δ7d +2.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
83
26% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
+33.5
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
52
34% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
-1.4
Why this grade

Composite grade B. Momentum 83.3 / Value 41.1 / Sentiment 51.7

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$964.09M
Beta
0.24
Shares Out
88.77M
P/E (TTM) · Derived
-3.4
P/S (TTM)
7.98
P/FCF (TTM)
9.99
Rev YoY
+29.5%
EPS YoY
+26.0%
Gross Margin
+98.0%
Op Margin
-230.5%
Net Debt
-$646.78M
Current Ratio
6.15
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology